- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00316134
Multiple Biomarkers in Undiagnosed Pleural Effusion
Evaluation of Multiple Biomarkers in Serum and Pleural Fluid to Estimate the Probability of Cancer in Patients Presenting With an Undiagnosed Pleural Effusion
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately 1.6 million cases of pleural effusion are seen in the US per year, with ~210,000 of those cases due to underlying malignancy. Pleural fluids have traditionally been divided into two types: transudative and exudative. The most common causes of transudative pleural effusion are congestive heart failure and cirrhosis. Common causes of exudative pleural effusion include malignancy, pneumonia, pulmonary embolism and viral infection. One study found that 42% of all exudative effusions were due to malignancy, and another found that malignancy was the underlying cause of 24% of all effusions. Differential diagnosis of the various causes of effusions is complex and includes gross appearance of the pleural fluid (PF), differential cell count, cytology, glucose and LDH levels, and sometimes adenosine deaminase (ADA) levels. In addition, spiral CT scans, bronchoscopy, thoracoscopy, needle biopsy of the pleura, and video assisted thoracoscopy (VATS) are all utilized to determine the underlying cause of pleural fluid accumulation. These procedures are expensive and may be traumatic to patients. In approximately 20% of patients presenting with pleural fluid accumulation, no underlying cause will be established. Despite promising results published in peer-reviewed journals over the last two decades, serum biomarkers have not gained acceptance as a standard of care in the management of patients with lung cancer, mesothelioma, or pleural effusion. The purpose of this clinical trial is to evaluate the ability of various biomarkers measured in serum and/or pleural fluids to estimate the risk of finding cancer in patients with undiagnosed pleural effusions. An algorithm for prediction of the risk of finding cancer in the patient using an optimal combination of markers will be developed, and patients will be categorized as having a low, moderate, or high risk of finding cancer that might be used to more effectively triage patients. For example, a high risk of cancer may be used to justify more invasive or expensive procedures, such as spiral CT scans and thoracoscopy.
This is a prospective, multi-center, double-blind, statistically powered clinical trial that will enroll patients scheduled to undergo a procedure for removal of fluid from a pleural effusion (i.e. thoracentesis, thoracoscopy, image guided thoracentesis, thoracotomy, chest tube placement, Pleurex® catheter insertion, etc.).
The primary objective of the study is to evaluate the ability of multiple biomarkers in serum and/or pleural fluid to estimate the risk of finding cancer in subjects presenting with an undiagnosed pleural effusion (i.e. unknown origin).
The secondary objective of the study is to compare the ability of multiple biomarkers in serum and/or pleural fluid combined with pleural fluid cytology and other laboratory results to the use of the multiple biomarkers alone to estimate the risk of finding cancer in subjects presenting with an undiagnosed pleural effusion.
The research objectives of the study are the evaluation of the utility of multiple biomarkers in serum and/or pleural fluid to predict the tissue of origin in subjects with cancer who presented with an undiagnosed pleural effusion and comparison of these results to pleural fluid cytology. Correlation of the biomarker levels in the serum and pleural fluid will be evaluated as well.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Malvern, Pennsylvania, United States, 19355
- Fujirebio Diagnostics, Inc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
TRAINING SET INCLUSION CRITERIA
- Subjects able to understand and sign Informed Consent;
- Males or females >18 years of age;
- Have a pleural effusion of known or unknown origin;
- Scheduled for a diagnostic and/or therapeutic procedure to remove pleural fluid.
VALIDATION SET INCLUSION CRITERIA
- Subjects able to understand and sign Informed Consent;
- Males or females >18 years of age;
- Have a pleural effusion of unknown origin;
- Scheduled for a diagnostic procedure to remove pleural fluid.
Exclusion Criteria:
TRAINING SET EXCLUSION CRITERIA
- For Subjects currently receiving chemotherapy and/or radiation therapy- Subjects who have received chemotherapy and/or radiation therapy must have completed these modalities one month before entering the study.
- Females known to be pregnant;
- Already entered into the study;
- Unable or unwilling to provide informed consent or is there a high risk that the subject may not comply with the protocol requirements
VALIDATION SET EXCLUSION CRITERIA
- For Subjects currently receiving chemotherapy and/or radiation therapy- Subjects who have received chemotherapy and/or radiation therapy must have completed these modalities one month before entering the study.
- Females known to be pregnant;
- Already entered into the study;
- Unable or unwilling to provide informed consent or is there a high risk that the subject may not comply with the protocol requirements
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Pts scheduled to remove pleural fluid
|
Diagnostic and/or therapeutic procedure to remove pleural fluid.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jeffrey Allard, PhD, Fujirebio Diagnostics, Inc.
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FDI-02 Pleural Effusion Study
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pleural Effusion, Malignant
-
Sheng HuWuhan Binhui Biotechnology Co., Ltd.RecruitingMalignant Pleural Effusion | Malignant Peritoneal EffusionChina
-
Huazhong University of Science and TechnologyUnknownMalignant Ascites | Malignant Pleural Effusion,China
-
Clover Biopharmaceuticals AUS Pty LtdCompletedMalignant Pleural EffusionsAustralia
-
Johns Hopkins UniversityEnrolling by invitationMalignant Pleural EffusionsUnited States
-
Singapore General HospitalCompletedMalignant Pleural EffusionsSingapore
-
Naestved HospitalTerminatedMalignant Pleural Effusion | Exudative Pleural EffusionDenmark
-
Wuhan YZY Biopharma Co., Ltd.Not yet recruitingA Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLCNSCLC Stage IV | Malignant Pleural EffusionsChina
-
M.D. Anderson Cancer CenterTerminatedAdvanced Cancers | Malignant Pleural EffusionsUnited States
-
Eastern Regional Medical CenterRecruitingLoculated or Non-draining Malignant Pleural EffusionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPleural NeoplasmUnited States
Clinical Trials on Procedure/Surgery
-
The Second Hospital of Shandong UniversityRecruiting
-
Shanghai Minimally Invasive Surgery CenterCompleted
-
Ecole Polytechnique Fédérale de LausanneNot yet recruiting
-
Postgraduate Institute of Dental Sciences RohtakCompleted
-
Duke UniversityMedShape, IncCompletedAnkle ArthritisUnited States
-
Universidade Federal de Sao CarlosFundação de Amparo à Pesquisa do Estado de São PauloRecruiting
-
Fundación Cardioinfantil Instituto de CardiologíaUniversidad del RosarioActive, not recruitingPostoperative Complications | Surgery | Hospital MortalityColombia
-
Pomeranian Medical University SzczecinCompletedPeripheral Arterial Disease | Aortic Aneurysm, Abdominal | Ventricular Arrythmia | Cardiac Complication
-
Hospital Universitario Virgen de la ArrixacaCompletedIleostomy; Complications
-
Mansoura UniversityCompleted